1.	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00507, E1305, CDR0000582533, U10CA021115, ECOG-E1305, NCT00588770
2.	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
3.	LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.131, 2011-000392-14, NCT01345669
4.	CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000727295, NCCTG-N11C5, N11C5, NCT01545687
5.	The Quarterback Trial Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO 12-1050, HS 12-00359, IF 1403412, NCT01706939
6.	Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 603EUSA03, NCT00901732
7.	Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 06-121, 1R21CA130241-01A1, NCT00903461
8.	Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-131, NCT01016769
9.	Study of PX-866 and Docetaxel in Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-866-002, NCT01204099
10.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
11.	A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBYL719X2104, 2011-006017-34, NCT01602315
12.	Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage III-IV Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02009, A091101, U10CA031946, N01CM62201, NCT01711541
13.	A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BrUOG 254, NCT01744340
14.	Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors Phase: Phase II Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: HSC-MS-04-259, NCT00178698
15.	Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570
16.	A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090214, 09-C-0214, NCT00978250
17.	A Study in Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075
18.	Study in Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13418, I4E-MC-JXBA, NCT01099358
19.	Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-01162, ENT0025, SUMC-ENT 0025, 8209, NCT00841997, NCT00896181
20.	Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCI 06-093, NCT01104922
21.	Randomized Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck Phase: Phase II Type: Treatment Status: Active Age: 18 to 89 Sponsor: Other Protocol IDs: 10-069-B, NCT01133678
22.	Paclitaxel, Carboplatin and Cetuximab (PCC) Versus Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0885, NCT01154920
23.	Minocycline in Oropharynx Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 2010-0096, NCT01173692
24.	Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02556, PHL-068, N01CM62203, N01CM00032, N01CM00038, PMH-PHL-068, 8192, NCT01267240
25.	Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02596, 10-428-B, CDR0000689896, UCCRC-10-428-B, N01CM00099, N01CM00071, 8692, NCT01256385